295 related articles for article (PubMed ID: 30336855)
1. Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic.
Calo G; Lambert DG
Br J Anaesth; 2018 Nov; 121(5):1105-1114. PubMed ID: 30336855
[TBL] [Abstract][Full Text] [Related]
2. Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors.
Sałat K; Jakubowska A; Kulig K
Expert Opin Investig Drugs; 2015 Jun; 24(6):837-44. PubMed ID: 25865744
[TBL] [Abstract][Full Text] [Related]
3. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model.
Christoph T; Raffa R; De Vry J; Schröder W
Pharmacol Res Perspect; 2018 Dec; 6(6):e00444. PubMed ID: 30519474
[TBL] [Abstract][Full Text] [Related]
5. Cebranopadol: novel dual opioid/NOP receptor agonist analgesic.
Raffa RB; Burdge G; Gambrah J; Kinecki HE; Lin F; Lu B; Nguyen JT; Phan V; Ruan A; Sesay MA; Watkins TN
J Clin Pharm Ther; 2017 Feb; 42(1):8-17. PubMed ID: 27778406
[TBL] [Abstract][Full Text] [Related]
6. Nociceptin/orphanin FQ opioid peptide (NOP) receptor and µ-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain.
Schiene K; Schröder W; Linz K; Frosch S; Tzschentke TM; Jansen U; Christoph T
Eur J Pharmacol; 2018 Aug; 832():90-95. PubMed ID: 29753041
[TBL] [Abstract][Full Text] [Related]
7. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
8. Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin/Orphanin FQ Peptide Receptor Agonist Activity.
Linz K; Schröder W; Frosch S; Christoph T
Anesthesiology; 2017 Apr; 126(4):708-715. PubMed ID: 28291086
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain.
Sałat K; Furgała A; Sałat R
Inflammopharmacology; 2018 Apr; 26(2):361-374. PubMed ID: 29071457
[TBL] [Abstract][Full Text] [Related]
10. Antihyperalgesic, Antiallodynic, and Antinociceptive Effects of Cebranopadol, a Novel Potent Nociceptin/Orphanin FQ and Opioid Receptor Agonist, after Peripheral and Central Administration in Rodent Models of Neuropathic Pain.
Tzschentke TM; Linz K; Frosch S; Christoph T
Pain Pract; 2017 Nov; 17(8):1032-1041. PubMed ID: 28112482
[TBL] [Abstract][Full Text] [Related]
11. Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers.
Dahan A; Boom M; Sarton E; Hay J; Groeneveld GJ; Neukirchen M; Bothmer J; Aarts L; Olofsen E
Anesthesiology; 2017 Apr; 126(4):697-707. PubMed ID: 28291085
[TBL] [Abstract][Full Text] [Related]
12. NOP agonist action of cebranopadol counteracts its liability to promote physical dependence.
Ruzza C; Holanda VA; Gavioli EC; Trapella C; Calo G
Peptides; 2019 Feb; 112():101-105. PubMed ID: 30550769
[TBL] [Abstract][Full Text] [Related]
13. A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism.
Fantinati A; Bianco S; Guerrini R; Salvadori S; Pacifico S; Cerlesi MC; Calo G; Trapella C
Sci Rep; 2017 May; 7(1):2416. PubMed ID: 28546566
[TBL] [Abstract][Full Text] [Related]
14. Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors.
Tzschentke TM; Linz K; Koch T; Christoph T
Handb Exp Pharmacol; 2019; 254():367-398. PubMed ID: 30927089
[TBL] [Abstract][Full Text] [Related]
15. Functional Profile of Systemic and Intrathecal Cebranopadol in Nonhuman Primates.
Ding H; Trapella C; Kiguchi N; Hsu FC; Caló G; Ko MC
Anesthesiology; 2021 Sep; 135(3):482-493. PubMed ID: 34237134
[TBL] [Abstract][Full Text] [Related]
16. Cebranopadol as a Novel Promising Agent for the Treatment of Pain.
Ziemichod W; Kotlinska J; Gibula-Tarlowska E; Karkoszka N; Kedzierska E
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807228
[TBL] [Abstract][Full Text] [Related]
17. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
18. Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test.
Rizzi A; Ruzza C; Bianco S; Trapella C; Calo' G
Peptides; 2017 Aug; 94():71-77. PubMed ID: 28697954
[TBL] [Abstract][Full Text] [Related]
19. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics.
Ding H; Kiguchi N; Dobbins M; Romero-Sandoval EA; Kishioka S; Ko MC
Drugs; 2023 Jun; 83(9):771-793. PubMed ID: 37209211
[TBL] [Abstract][Full Text] [Related]
20. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
